Literature DB >> 34742788

Harms in Systematic Reviews Paper 1: An introduction to research on harms.

Riaz Qureshi1, Evan Mayo-Wilson2, Tianjing Li3.   

Abstract

OBJECTIVE: Most systematic reviews of interventions focus on potential benefits. Common methods and assumptions that are appropriate for assessing benefits can be inappropriate for harms. This paper provides a primer on researching harms, particularly in systematic reviews. STUDY DESIGN AND
SETTING: Commentary describing challenges with assessing harm.
RESULTS: Investigators should be familiar with various terminologies used to describe, classify, and group harms. Published reports of clinical trials include limited information about harms, so systematic reviewers should not depend on these studies and journal articles to reach conclusions about harms. Visualizations might improve communication of multiple dimensions of harms such as severity, relatedness, and timing.
CONCLUSION: The terminology, classification, detection, collection, and reporting of harms create unique challenges that take time, expertise, and resources to navigate in both primary studies and evidence syntheses. Systematic reviewers might reach incorrect conclusions if they focus on evidence about harms found in published reports of randomized trials of a particular health problem. Systematic reviews could be improved through better identification and reporting of harms in primary studies and through better training and uptake of appropriate methods for synthesizing evidence about harms.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Clinical Trials; Harms; Meta-analysis; Synthesis; Systematic Reviews

Mesh:

Year:  2021        PMID: 34742788      PMCID: PMC9126149          DOI: 10.1016/j.jclinepi.2021.10.023

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   7.407


  63 in total

Review 1.  Quantifying adverse drug events : are systematic reviews the answer?

Authors:  Mahyar Etminan; Bruce Carleton; Paula A Rochon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

2.  Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality.

Authors:  V R Cornelius; M J Perrio; S A W Shakir; L A Smith
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

3.  Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.

Authors:  Evan Mayo-Wilson; Nicole Fusco; Tianjing Li; Hwanhee Hong; Joseph K Canner; Kay Dickersin
Journal:  J Clin Epidemiol       Date:  2019-05-02       Impact factor: 6.437

4.  Time to improve the reporting of harms in randomized controlled trials.

Authors:  Daniela R Junqueira; Rachel Phillips; Liliane Zorzela; Su Golder; Yoon Loke; David Moher; John P A Ioannidis; Sunita Vohra
Journal:  J Clin Epidemiol       Date:  2021-05-10       Impact factor: 6.437

Review 5.  An appraisal of meta-analysis guidelines: how do they relate to safety outcomes?

Authors:  Meg Bennetts; Ed Whalen; Sima Ahadieh; Joseph C Cappelleri
Journal:  Res Synth Methods       Date:  2016-09-09       Impact factor: 5.273

6.  Do physicians communicate the adverse effects of medications that older patients want to hear?

Authors:  Derjung M Tarn; Ariela Wenger; Jeffrey S Good; Marc Hoffing; Joseph E Scherger; Neil S Wenger
Journal:  Drugs Ther Perspect       Date:  2015-02

Review 7.  Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy.

Authors:  Evan Mayo-Wilson; Tianjing Li; Nicole Fusco; Lorenzo Bertizzolo; Joseph K Canner; Terrie Cowley; Peter Doshi; Jeffrey Ehmsen; Gillian Gresham; Nan Guo; Jennifer A Haythornthwaite; James Heyward; Hwanhee Hong; Diana Pham; Jennifer L Payne; Lori Rosman; Elizabeth A Stuart; Catalina Suarez-Cuervo; Elizabeth Tolbert; Claire Twose; Swaroop Vedula; Kay Dickersin
Journal:  J Clin Epidemiol       Date:  2017-08-24       Impact factor: 6.437

8.  Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms.

Authors:  Riaz Qureshi; Evan Mayo-Wilson; Thanitsara Rittiphairoj; Mara McAdams-DeMarco; Eliseo Guallar; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2021-11-03       Impact factor: 6.437

9.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Authors:  JoAnn E Manson; Rowan T Chlebowski; Marcia L Stefanick; Aaron K Aragaki; Jacques E Rossouw; Ross L Prentice; Garnet Anderson; Barbara V Howard; Cynthia A Thomson; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson; Marian Limacher; Karen L Margolis; Sylvia Wassertheil-Smoller; Shirley A Beresford; Jane A Cauley; Charles B Eaton; Margery Gass; Judith Hsia; Karen C Johnson; Charles Kooperberg; Lewis H Kuller; Cora E Lewis; Simin Liu; Lisa W Martin; Judith K Ockene; Mary Jo O'Sullivan; Lynda H Powell; Michael S Simon; Linda Van Horn; Mara Z Vitolins; Robert B Wallace
Journal:  JAMA       Date:  2013-10-02       Impact factor: 56.272

Review 10.  The Use of Social Media in Detecting Drug Safety-Related New Black Box Warnings, Labeling Changes, or Withdrawals: Scoping Review.

Authors:  Jae-Young Lee; Yae-Seul Lee; Dong Hyun Kim; Han Sol Lee; Bo Ram Yang; Myeong Gyu Kim
Journal:  JMIR Public Health Surveill       Date:  2021-06-28
View more
  1 in total

1.  Harms in Systematic Reviews Paper 1: An introduction to research on harms.

Authors:  Riaz Qureshi; Evan Mayo-Wilson; Tianjing Li
Journal:  J Clin Epidemiol       Date:  2021-11-03       Impact factor: 7.407

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.